Insulin secretion and sensitivity as determinants of HbA1c in type 2 diabetes

European Journal of Clinical Investigation

Volumn 36, Issue 4, 2006, Pages 231-235

  Monnier, L ^a   Colette, C ^b   Thuan, J F ^a   Lapinski, H ^b  

^a LAPEYRONIE HOSPITAL   (France)

^b UNIV MONTPELLIER   (France)

Author keywords

Glyburide; HbA1c; HOMA2 B; HOMA2 S; Metformin; Type 2 diabetes

Indexed keywords

GLIBENCLAMIDE; HEMOGLOBIN A1C; INSULIN; METFORMIN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; HOMEOSTASIS; HUMAN; INSULIN RELEASE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIPLE REGRESSION; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; FEMALE; GLYBURIDE; HEMOGLOBIN A, GLYCOSYLATED; HOMEOSTASIS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; MALE; METFORMIN; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 33645324753     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01623.x     Document Type: Article

References (26)

1. UK prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet 1998 352 837 53
2. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) Lancet 1998 352 854 65
3. Le Roith D. β-cell dysfunction and insulin resistance in type 2 diabetes: role of metabolic and genetic abnormalities Am J Med 2002 113 3S 11S
4. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes Diabetologia 2003 46 3 19
5. DeFronzo RA. Lilly lecture: the triumvirate: β-cell, muscle, liver: a collusion responsible for NIDDM Diabetes 1998 37 667 87
6. DeFronzo RA. Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes Diabetes Rev 1997 5 177 269
7. Weyer C Bogardus C Mott DM Pratley RE. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus J Clin Invest 1999 104 787 94
8. Pratley RE Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus Diabetologia 2001 44 929 45
9. Tripathy D Eriksson KF Ortho-Melander M Frederiksson J Ahlqvist G Groop L. Parallel insulin resistance and beta-cell decompensation in Type 2 diabetes Diabetologia 2004 47 782 93
10. Grodsland IF Jeff JAR Johnston DG. Loss of beta-cell function as fasting glucose increases in the non-diabetic range Diabetologia 2004 47 1157 66
11. UK Prospective Diabetes Study Group 16. Overview of 6 year's therapy of type 2 diabetes: a progressive disease Diabetes 1995 44 1249 58
12. Levy J Atkinson AB Bell PM McCance DR Hadden DR. Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast diet study Diab Med 1998 15 290 6
13. Einhorn D Rendell M Rosenzweig J Egan JW Mathisen AL Schneider RL. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study: the Pioglitazone 027 Study Group Clin Ther 2000 22 1395 409
14. Fonseca V Rosenstock J Patwardhan R Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial JAMA 2000 283 1695 702
15. Wallace TM Levy JC Matthews DR. Use and abuse of HOMA modeling Diabetes Care 2004 27 1487 95
16. Zar JH Biostatistical Analysis 4th edn New Jersey, NJ Prentice Hall Inc. 1999 663
17. Ceriello A Johns D Widel M Eckland DJ Gilmore KJ Tan MH. Comparison of effects of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes Diabetes Care 2005 28 266 72
18. Jones TA Sautter M Van Gaal LF Jones NP. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes Diabetes Obes Metab 2003 5 163 70
19. Matthews DR Charbonnel BH Hanefeld M Brunetti P Schernthaner G. Long-term therapy with addition of gliclazide to metformin in patients with type 2 diabetes: a randomised comparative study Diabetes Metab Res Rev 2005 21 167 74
20. Yki-Järvinen H. Role of insulin resistance in the pathogenesis of NIDDM Diabetologia 1995 38 1378 88
21. De Witt DR Hirsh JB. Outpatient insulin therapy in type 1 and 2 diabetes mellitus JAMA 2003 289 2254 64
22. Nathan DM. Initial management of glycemia in type 2 diabetes mellitus N Engl J Med 2002 347 1342 9
23. Aljabri K Kozak SE Thompson DM. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial Am J Med 2004 116 230 5
24. Dailey GE Noor MA Park J-S Bruce S Fiedorek FT. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized double-blind trial Am J Med 2004 116 223 9
25. Roy R Navar M Palomeno G Davidson MB. Real world effectiveness of rosiglitazone added to maximal (tolerated) doses of metformin and sulfonylurea agent Diabetes Care 2004 27 1741 2
26. Yki-Järvinen H. Combination therapies with insulin in type 2 diabetes Diabetes Care 2001 24 758 67